Sophia Genetics SA (SOPH)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $703.25M
Last updated: Nov 17, 2026 at 11:06 AM ET
Sophia Genetics SA (SOPH) Stock Forecast
Analysts expect Sophia Genetics SA (SOPH) to earn -$0.88 per share in the fiscal year ending Dec 31, 2026, on revenue of $95.57M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 24.3%.
- Fiscal year ending Dec 31, 2026
- -$0.88
- EPS consensus, revenue $95.57M
- Fiscal year ending Dec 31, 2027
- -$0.55
- EPS consensus, revenue $118.78M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.88 | -$0.88 to -$0.88 | 1 | $95.57M | $95.20M to $95.90M | 5 |
| Dec 31, 2027 | -$0.55 | -$0.55 to -$0.55 | 1 | $118.78M | $114.10M to $128.12M | 5 |
Quarterly Estimates
The EPS consensus falls from -$0.16 for the quarter ending Dec 31, 2026 to -$0.18 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.16 | -$0.20 to -$0.06 | 7 | $26.76M | $25.38M to $27.93M | 7 |
| Mar 31, 2027 | -$0.18 | -$0.18 to -$0.18 | 1 | $26.17M | $25.39M to $27.00M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.85.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.88 | -$0.85 | -$0.85 | -$0.85 | -$0.85 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.55 | -$0.50 | -$0.50 | -$0.50 | -$0.50 | N/A |
| Quarter ending Mar 31, 2027 | -$0.18 | -$0.17 | -$0.17 | -$0.17 | -$0.17 | N/A |
Frequently Asked Questions About SOPH
What is the SOPH stock forecast?
Consensus analyst estimates put Sophia Genetics SA's EPS at -$0.88 for the fiscal year ending Dec 31, 2026, on revenue of $95.57M. The consensus rating from 5 analysts is Buy.
How do analysts rate SOPH stock?
Of 5 analysts covering Sophia Genetics SA, 0 rate it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from SOPH next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.88, with estimates from -$0.88 to -$0.88 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.55, with estimates from -$0.55 to -$0.55 from 1 analyst.
What revenue do analysts expect from Sophia Genetics SA next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $95.57M, with estimates from $95.20M to $95.90M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $118.78M, with estimates from $114.10M to $128.12M.
How many analysts cover SOPH?
5 analysts rate Sophia Genetics SA stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
SOPH pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts